Adamas Pharmaceuticals
ADMS
ADMS was delisted on the 23rd of November, 2021.
126 hedge funds and large institutions have $676M invested in Adamas Pharmaceuticals in 2018 Q2 according to their latest regulatory filings, with 22 funds opening new positions, 54 increasing their positions, 33 reducing their positions, and 13 closing their positions.
69% more first-time investments, than exits
New positions opened: 22 | Existing positions closed: 13
64% more repeat investments, than reductions
Existing positions increased: 54 | Existing positions reduced: 33
31% more call options, than puts
Call options by funds: $8.34M | Put options by funds: $6.37M
12% more capital invested
Capital invested by funds: $602M → $676M (+$74.7M)
7% more funds holding
Funds holding: 118 → 126 (+8)
20% less funds holding in top 10
Funds holding in top 10: 5 → 4 (-1)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
PA
Perceptive Advisors
New York
|
+$12.6M |
| 2 |
BlackRock
New York
|
+$10M |
| 3 |
BC
Broadfin Capital
New York
|
+$7.81M |
| 4 |
SI
Sofinnova Investments
Menlo Park,
California
|
+$7.4M |
| 5 |
Millennium Management
New York
|
+$7.21M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
State Street
Boston,
Massachusetts
|
-$16.9M |
| 2 |
Fidelity Investments
Boston,
Massachusetts
|
-$9.4M |
| 3 |
KA
Kerrisdale Advisers
Miami,
Florida
|
-$7.27M |
| 4 |
UBS Group
Zurich,
Switzerland
|
-$5.29M |
| 5 |
BWCA
Brenner West Capital Advisors
New York
|
-$4.41M |
ADMS Hedge Fund Activity: Q2 2018 in Review
126 of the 4,368 institutional investors tracked by Wall St. Rank reported a position in Adamas Pharmaceuticals (ADMS) for Q2 2018, worth a combined $676M — up 12% from $602M a quarter earlier.
Buyers outnumbered sellers: 22 funds opened new ADMS positions and 13 closed out — a net gain of 9 holders — while 54 added to existing stakes and 33 trimmed.
The largest buyer was Perceptive Advisors, adding an estimated $12.6M. The largest seller was State Street, cutting an estimated $16.9M.
- 126 institutional investors held Adamas Pharmaceuticals (ADMS) as of Q2 2018, up from 118 in Q1 2018.
- Funds reported $676M of Adamas Pharmaceuticals stock for Q2 2018, up 12% quarter-over-quarter.
- 22 funds opened new Adamas Pharmaceuticals positions in Q2 2018 and 13 closed out, a net change of +9 holders.
- The largest Adamas Pharmaceuticals buyer in Q2 2018 was Perceptive Advisors, an estimated $12.6M added.
- The largest Adamas Pharmaceuticals seller in Q2 2018 was State Street, an estimated $16.9M sold.
Based on aggregated 13F filings for Q2 2018.